Back

The safety and efficacy of istaroxime for PreCardiogenic Shock

23 May 2022 (15:50 - 16:02)
Organised by:
Congress Presentation Part of: Late-Breaking Trials - Pharmacological treatment II Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Professor Marco Metra

IRCCS San Raffaele Scientific Institute, Milan (Italy)

4 More presentations in this session

Presentation thumbnail
Short-term effects of dapagliflozin on peak VO2 in heart failure and reduced ejection fraction (DAPA-VO2): a randomized clinical trial
Doctor J. Nunez Villota (Valencia, ES)
Slides Video
Presentation thumbnail
DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for Heart Failure with Reduced Ejection Fraction
Professor B. Pitt (Ann Arbor, US)
Slides Video
Presentation thumbnail
EMPULSE - EMPagliflozin in patients hospitalized with acUte heart faiLure who have been StabilizEd
Professor P. Ponikowski (Wroclaw, PL)
Slides Video
Presentation thumbnail
FIDELITY: Effect of finerenone by LVH subgroup
Professor G. Filippatos (Athens, GR)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Trials - Pharmacological treatment II
Video

The Event

Event poster

Heart Failure 2022

23 May 2022 15:50 CET
You may be interested in
thumbnail
Congress Presentation
A multicenter, randomized, double-blind, placebo-controlled, parallel group study on the safety and efficacy of istaroxime for pre-cardiogenic shock
19 May 2025
thumbnail
Congress Session
State of the art: cardiogenic shock
23 May 2023
thumbnail
Congress Session
Advances in cardiomyopathies
11 May 2026
thumbnail
Congress Session
HOT LINE SESSION 2
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources